Emerging Infections and Pregnancy by Jamieson, Denise J. et al.
A key component of the response to emerging infec-
tions is consideration of special populations, including
pregnant women. Successful pregnancy depends on adap-
tation of the woman’s immune system to tolerate a geneti-
cally foreign fetus. Although the immune system changes
are not well understood, a shift from cell-mediated immuni-
ty toward humoral immunity is believed to occur. These
immunologic changes may alter susceptibility to and sever-
ity of infectious diseases in pregnant women. For example,
pregnancy may increase susceptibility to toxoplasmosis
and listeriosis and may increase severity of illness and
increase mortality rates from influenza and varicella.
Compared with information about more conventional dis-
ease threats, information about emerging infectious dis-
eases is quite limited. Pregnant women’s altered response
to infectious diseases should be considered when planning
a response to emerging infectious disease threats.
A
s strategies to deal with emerging infectious disease
threats are developed, a key component is considera-
tion of special populations, including pregnant women (1).
Several issues are relevant to infectious disease threats
during pregnancy. First, changes in immunity and physiol-
ogy during pregnancy may make pregnant women more
susceptible to or more severely affected by infectious dis-
eases. Second, the effects of infectious diseases on the
fetus may be unknown and difficult to predict, and diagno-
sis of infection in the fetus or infant can be challenging.
Third, prophylaxis and treatment appropriate for the gen-
eral population might not be appropriate for pregnant
women. We focus on the first of these considerations: the
immunology of pregnancy and the effects of emerging
infectious diseases on the pregnant woman.
Although knowledge of the immunology of pregnancy
has evolved tremendously over the past decade, many
unanswered questions remain, such as how immune func-
tion is altered during pregnancy and how this alteration
may affect susceptibility to and severity of infectious dis-
eases. Although the effects of some infectious agents dur-
ing pregnancy are well known, knowledge about many
others is limited. Achallenge to the study of infectious dis-
eases during pregnancy is the selection of an appropriate
control group; many studies have been retrospective and
without control groups. Compared with knowledge about
more conventional infectious disease threats, knowledge
about novel and emerging infectious diseases during preg-
nancy is even more limited. Such lack of knowledge caus-
es concern, given that an altered response to infectious
diseases during pregnancy may require altered responses
to emerging infectious disease threats. We describe the
immunologic changes that may affect the course of infec-
tious diseases in pregnant women, briefly summarize what
is known about infectious diseases during pregnancy, and
then focus on the particular challenges of dealing with
emerging infectious diseases in pregnant women.
Immunology of Pregnancy
One of the most intriguing puzzles in modern immunol-
ogy involves the “paradox of pregnancy,” in which
immunologic tolerance to paternally derived fetal antigens
is achieved despite an apparently adequate maternal
defense against infection. With 50% of its genetic material
derived from its father, the fetus’s susceptibility to rejec-
tion by the maternal immune system is similar to the sus-
ceptibility of a transplanted organ. Evidence indicates that
the maternal immune system may tolerate fetal antigens by
suppressing cell-mediated immunity while retaining nor-
mal humoral immunity. These changes are known to occur
locally at the maternal-fetal interface but may also affect
systemic immune responses to infection. Although preg-
nant women are not immunosuppressed in the classic
sense, immunologic changes of pregnancy may induce a
state of increased susceptibility to certain intracellular
pathogens, including viruses, intracellular bacteria, and
parasites.
Maternal-Fetal Interface
The fetal allograft is exposed to the maternal immune
system at the placenta and fetal membranes (the amnion
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interface. On the fetal side of the interface, the placenta
and membranes enclose the fetus and are derived entirely
from fetal tissue. Forming a specialized epithelial surface
within the placenta, fetal syncytiotrophoblast cells directly
contact maternal blood for nutrient exchange. On the
maternal side of the interface, the uterine tissue in contact
with the placenta and fetal membranes, the decidua, is rich
in specialized maternal immune cells including lympho-
cytes and macrophages (2). Despite the prolonged direct
exposure of decidual leukocytes and maternal blood to
fetal antigens, the immune system does not recognize the
fetus as foreign. Several mechanisms underlie this mater-
nal tolerance of fetal tissues.
Humoral Immunity
Also known as antibody-mediated immunity, humoral
immunity results from recognition of pathogens by specif-
ic antibodies. Most effective against extracellular
pathogens, humoral immunity is essential for fighting
many bacterial infections. The bacteria become coated in
antibodies, which then mediate uptake of the pathogens by
phagocytic cells, including neutrophils and macrophages.
Presentation of the bacterial antigens on the surface of the
macrophage then stimulates B lymphocytes specific to the
pathogen, and the B cells produce more antibodies to con-
trol the infection. This humoral immune response is aug-
mented by T-helper type II (Th2) lymphocytes, which
provide costimulation and induce replication of the B cells.
The Th2 response during pregnancy results in vigorous
antibody-mediated immunity to pathogens (2).
Cell-Mediated Immunity
Essential for controlling intracellular pathogens, cell-
mediated immunity involves lymphocyte recognition of
cell-associated foreign antigens, followed by destruction
of the infected host cells. In contrast to humoral immunity,
this arm of the immune response is stimulated by T-helper
type I (Th1) lymphocytes and the cytokines they release.
The most important effectors of the cell-mediated immune
response, cytotoxic T lymphocytes, are the main immune
cells that recognize foreign antigens on the surface of
infected “self” cells. Cells infected with viruses or other
intracellular pathogens are cytotoxic T lymphocytes’ most
common targets. The cell-mediated immune response is
critical for controlling such pathogens because their intra-
cellular location shelters them from antibody binding.
T-Helper Cells and the Th1-Th2 Shift
Emphasis on cell-mediated immunity versus humoral
immunity changes according to the type of T-helper lym-
phocytes responding to an infectious threat. Multiple fac-
tors, including the cytokine environment and
costimulatory molecules present during activation of the T-
helper cell, determine the development of either Th1- or
Th2-helper phenotype. One hypothesis is that, in addition
to hormonal factors that affect the Th1-Th2 balance,
macrophages present at the maternal-fetal interface release
predominantly Th2-stimulating cytokines and contribute
to the overall dominance of humoral immunity during
pregnancy (3). In addition to stimulating B lymphocytes,
Th2 cells suppress the cytotoxic T lymphocyte response,
decreasing the robustness of cell-mediated immunity. In
the uterine decidua, the Th2 cytokine environment favors
activation of B lymphocytes, resulting in stimulation of
antibody secretion and suppression of cell-mediated
immunity (3). This phenomenon is often referred to as the
Th1-Th2 shift of pregnancy and is thought to contribute to
maternal tolerance of the fetus by suppressing the antifetal
cell-mediated immune response.
Systemic Immune Changes 
An evolving model of pregnancy-associated immune
changes suggests that the hormonal environment of preg-
nancy contributes to local suppression of cell-mediated
immunity at the maternal-fetal interface while mediating a
systemic change toward Th2 dominance. That the local
Th1-Th2 shift may also influence the systemic maternal
immune response during pregnancy is evidenced in preg-
nant patients with autoimmune disorders. Women with
rheumatoid arthritis, a predominantly cell-mediated
autoimmune disorder, tend to experience remissions dur-
ing pregnancy (4). Similarly, patients with multiple scle-
rosis have fewer exacerbations while pregnant but
worsening symptoms during the postpartum period (5).
Systemic lupus erythematosis, however, a predominantly
antibody-mediated autoimmune disorder, often worsens
during pregnancy, perhaps due to increased immunoglob-
ulin synthesis and decreased clearance of immune com-
plexes resulting from robust Th2 activity (3,6). These
well-studied changes in severity of autoimmune disorders
during pregnancy illustrate systemic immune alterations
that occur in conjunction with the Th1-Th2 shift.
Systemic suppression of cell-mediated immunity may
contribute to increased susceptibility to some intracellular
pathogens—including viruses, bacteria, and parasites—
during pregnancy.
Pregnancy and Conventional Infectious 
Disease Threats
Pregnant women may be more susceptible and more
severely affected by several infectious diseases such as
malaria and measles. Pregnant women in malaria-endemic
regions are at risk of becoming infected with Plasmodium
falciparum, 1 of 4 parasites that cause malaria in humans
(7). The increased incidence and severity of malaria may
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density is highest in nonimmune women during their first
pregnancy, even a previously immune woman can become
more susceptible to malaria infection during pregnancy
(7). In a 14-year follow-up study of women of reproduc-
tive age (15–45 years) in 1 area of the Gambia, McGregor
and Smith found a higher prevalence of parasitemia among
pregnant women than among nonpregnant women (8).
Prevalence of infection and parasite density are highest
during the first half of pregnancy and decline gradually
during the second half (7).
Evidence also indicates that measles (rubeola) is more
common and severe in pregnant women. Accounts of
measles outbreaks before an effective vaccine was avail-
able indicate that pregnant women may be more severely
affected. For example, the investigation of an outbreak of
measles in Greenland in 1951 showed that mortality rates
were higher among pregnant women than nonpregnant
women. Pregnant women were also more likely to experi-
ence heart failure (9). A relatively recent outbreak of
>1,700 confirmed cases of measles in Houston during
1988–1989 also resulted in a high rate of serious compli-
cations among infected pregnant women, which suggests
that the outbreak disproportionately affected pregnant
women (10).
Increased Disease Susceptibility 
Pregnancy may be a risk factor for acquiring certain
infectious diseases, such as toxoplasmosis, Hansen dis-
ease, and listeriosis. Toxoplasma gondii is a parasite that
infects humans primarily through ingestion of infected raw
or undercooked meat and, less frequently, by exposure to
infected cat feces. This intracellular pathogen can be trans-
mitted transplacentally to the fetus. Across-sectional study
of 2,242 women in Brazil showed that previous pregnancy
was a risk factor for serologic evidence of prior infection
with toxoplasmosis (11). In a follow-up prospective cohort
study, the same investigators found that pregnant women
who were seronegative for Toxoplasma were more than
twice as likely as nonpregnant women to seroconvert;
acute infection developed in 8.6% of pregnant women
(12). These findings are consistent with animal data show-
ing that pregnant mice have lower resistance to
Toxoplasma than nonpregnant control mice (13).
Pregnant women may be more likely to show clinical
signs of Hansen disease, or leprosy. The causative agent,
Mycobacterium leprae, can multiply and cause sympto-
matic disease, particularly in hosts with decreased immu-
nity. The decreased cell-mediated immunity associated
with pregnancy may predispose pregnant women to this
disease (14). A recent report describes a cohort of 40
patients with Hansen disease in Texas, 3 of whom were
pregnant (14). In addition to evidence supporting the
theory that pregnant women are more susceptible to
Hansen disease, evidence exists that pregnant women may
be more likely to experience relapse of disease. Among 25
women in an Ethiopian cohort who had been treated and
had therapy discontinued when considered cured, almost
half (n = 12) experienced a relapse of disease when they
became pregnant (15).
Listeria monocytogenes, a foodborne pathogen, is
responsible for ≈2,500 cases of serious illness in the
United States each year. Listeria infections are more com-
mon during pregnancy; one quarter to one third of all cases
of listeriosis occur in pregnant women (16,17).  In 2000,
an outbreak of listeriosis among Hispanic persons in North
Carolina was reported as a result of ingestion of contami-
nated homemade Mexican-style cheese; 11 of the 13 cases
were in pregnant women (18).
Increased Disease Severity
For pregnant women, certain infectious diseases, such
as influenza and varicella, may have a more severe clinical
course, increased complication rate, and higher case-fatal-
ity rate. For example, influenza infections cause more
severe illness and higher mortality rates for pregnant
women. During the 1918–19 influenza pandemic, the mor-
tality rate was 27% for pregnant women, higher in the last
trimester, and it increased to 50% if pneumonia developed
(19). Freeman and Barno reported that during the
1957–1958 pandemic, 50% of the deaths from influenza
among reproductive-aged women in Minnesota occurred
in pregnant women and that influenza was the leading
cause of maternal death in Minnesota (20). Increased inci-
dence and severity of illness has also been observed during
interpandemic periods. In a review of the Tennessee
Medicaid program from 1974 through 1993, pregnant
women in their third trimester were 3–4 times as likely as
postpartum women to be hospitalized for an acute car-
diopulmonary condition during influenza season (21).  In
addition to immunologic changes, other physiologic
changes in pregnancy such as increased heart rate, stroke
volume, and oxygen consumption, and decreased lung
capacity may contribute to this increased risk for illness
during pregnancy. Due to the high risk for influenza-relat-
ed complications, women who will be pregnant during the
influenza season should be vaccinated (22).
Clinical evidence indicates that primary varicella infec-
tions during pregnancy tend to be more severe and that
varicella pneumonia seems to be more common among
pregnant women than among nonpregnant women. For
example, in a case-series of 43 pregnant women reported
by Paryani and Arvin, pneumonia developed in ≈10%; 2 of
these women required ventilatory support and 1 died (23).
By comparison, the rate of pneumonia as a complication of
varicella infection among the general population is
PERSPECTIVE
1640 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 11, November 20060.3%–1.8% (24). Similarly, pregnant women with varicella
pneumonia are more likely to die than nonpregnant women
with varicella pneumonia. Haake reviewed 34 published
cases of untreated varicella pneumonia in pregnant women
and found that 12 (35%) died. By contrast, the mortality
rate for nonpregnant women with varicella pneumonia is
≈11% (24).
Challenges 
Emerging infectious diseases, defined as infectious dis-
eases whose incidence in humans has increased during the
past 2 decades or threatens to increase in the near future,
are increasingly recognized by physicians as an important
threat to pregnant women. Emerging infectious diseases
include novel pathogens that have newly emerged, such as
severe acute respiratory syndrome (SARS), as well as
pathogens that could potentially be used as biologic
weapons. Unfortunately, information about how pregnant
women are affected by many of these novel and emerging
infections is limited. 
Novel Pathogens 
During the worldwide outbreak of SARS in 2003, sev-
eral countries reported cases in pregnant women. Although
these numbers were too small to enable definitive conclu-
sions as to whether SARS was more severe among preg-
nant than nonpregnant women, some evidence indicates
that it may be. The largest case series of pregnant women
with SARS was from Hong Kong Special Administrative
Region, People’s Republic of China, where 12 pregnant
women with SARS were admitted to 5 public hospitals; 3
of them died, giving a case-fatality rate of 25% (25). In a
case-control study conducted in the same region, pregnant
women with SARS had more severe disease than nonpreg-
nant women and an increased risk for admission to the
intensive care unit, development of renal failure, develop-
ment of disseminated intravascular coagulopathy, and
death (26). Of 8 cases of laboratory-confirmed SARS
reported in the United States, 2 were in pregnant women;
the small number of cases precludes definitive conclusions
about the severity of disease (27).
Potential Effects of Bioterrorism 
The Working Group on Civilian Biodefense has identi-
fied a limited number of biologic agents that are of partic-
ular concern (28). Evidence exists that infection with some
of these pathogens, including smallpox virus and some of
the hemorrhagic fever viruses, may be more severe during
pregnancy.
Clinical experience with smallpox (variola virus)
before vaccination and disease eradication indicates that
pregnant women are more susceptible to variola infection
and have more severe disease (29,30). Pregnancy is asso-
ciated with an increased smallpox case-fatality rate; in the
large case-series study in India reported by Rao et al.,
unvaccinated pregnant women were 3 times more likely to
die than were nonpregnant women and men admitted to the
hospital during the same time period (29). Pregnant
women are more likely than nonpregnant women to have
hemorrhagic smallpox (purpura variolosa), a severe vari-
ety of the disease (30).
The viral hemorrhagic fevers, including Lassa fever
and Ebola, may be more severe during pregnancy. The first
reported case of Lassa fever, caused by infection with an
arenavirus, was described in a pregnant patient. In this ini-
tial outbreak, 11 patients and staff members who were
exposed to the index patient died (31). The case-fatality
rate is higher for pregnant women, particularly in the third
trimester, than for nonpregnant women (31,32). Women
who have Lassa fever late in pregnancy have the highest
circulating levels of viremia and therefore tend to be the
sickest. Evidence indicating that the placenta may be a pre-
ferred site for viral replication may help explain why ill-
ness and death increase during the third trimester of
pregnancy (32). One study found that after pregnancy
ended, whether by abortion or normal delivery, women
rapidly improved (32).
Ebola virus, a member of the Filoviridae group, is
transmitted by direct contact with blood, secretions, or
contaminated objects and is associated with high case-
fatality rates (28). Investigations of outbreaks in Africa
suggest that Ebola infection may be more severe during
pregnancy and that mortality rates are higher. Pregnant
women infected with Ebola more often have serious com-
plications, such as hemorrhagic and neurologic sequelae,
than do nonpregnant patients (31). Unlike risk for death
from Lassa fever, which is highest during the third
trimester of pregnancy, risk for death from Ebola is similar
during all trimesters (33).
Other Emerging Infections 
Pneumocystis jiroveci (formerly  P. carinii) has long
been identified as a cause of pneumonia in immunocom-
promised persons. Pneumocytis pneumonia was first iden-
tified in malnourished children in European orphanages
during World War II and was later associated with severe
immunosuppression in HIV-infected persons (34).
However, this agent is increasingly causing infection
among immunocompetent persons. A mild or asympto-
matic form of P. jiroveci infection occurs in immunocom-
petent hosts, and this infection may be more common in
pregnant women than in nonpregnant women. In a small
pilot study, nasal swabs from 33 healthy women in their
third trimester of pregnancy were compared with those
from 28 healthy nonpregnant women. P. jiroveci DNAwas
isolated from 5 of the pregnant women and none of the
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the immune changes associated with pregnancy may favor
asymptomatic nasal carriage of this organism. Evidence
also indicates that Pneumocytis pneumonia may be more
severe during pregnancy (35) and that Pneumocystis may
be perinatally transmitted by HIV-infected women to their
children (34).
Psittacosis is primarily a flulike illness characterized by
fever, headache, and atypical pneumonia. Chlamydophila
psittaci (formerly Chlamydia psittaci), the causative agent,
is transmitted by inhalation of material from infected birds
or by exposure to infected amniotic fluid or placentas of
sheep or goats. Although each year, ≈75–100 cases of psit-
tacosis occur in the United States, only 14 cases of psitta-
cosis have been reported in pregnant women, including a
recent case in a pregnant Montana sheep rancher. Illness
during pregnancy can be quite severe, mimicking HELLP
(hemolysis, elevated liver enzyme levels, and low platelet
count) syndrome but without hypertension. Most women
rapidly recover after pregnancy (36).
Conclusions
Changes in immune function during pregnancy alter a
pregnant woman’s susceptibility to and severity of certain
infectious diseases. These alterations are particularly prob-
lematic because physicians may hesitate to provide pro-
phylaxis or aggressive treatment to pregnant women
because of concerns about effects on the fetus. For exam-
ple, despite the 1997 recommendation that women who
would be in their second or third trimester of pregnancy
during influenza season receive the inactivated influenza
vaccine, among women 18–44 years of age, reports of hav-
ing received the influenza vaccination during the past 12
months were fewer for pregnant than for nonpregnant
women (37).
Compared with what is known about conventional dis-
ease threats, knowledge about currently recognized emerg-
ing infectious diseases is quite limited. Soon we will likely
be faced with novel pathogens about which little or noth-
ing is known. Because the effects of emerging infections in
pregnant women might differ from those in the general
population, pregnancy must be considered a potential risk
factor for disease susceptibility as well as for illness and
death. Unfortunately, pregnancy issues are often not well
addressed in outbreak investigations, ongoing prospective
studies, or emergency preparedness planning. Future sci-
entific inquiry and medical investigations must include
pregnancy-related issues as a vital component.
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